BioSpace News Archive

Histogen Inc. (NASDAQ: HSTO), today reported financial results for the second quarter ended June 30, 2022 and provided an update on its clinical pipeline and other corporate developments.

Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced its financial results for the second quarter that ended June 30, 2022.

BIOLASE, Inc., the global leader in dental lasers, announced its financial results for the second quarter ended June 30, 2022.

Poseida Therapeutics, Inc. announced business updates and financial results for the second quarter ended June 30, 2022.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for four generics products, including vasopressin injection 1mL (single-dose).

Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the second quarter of 2022, ended June 30, 2022.

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced that data from the core period of the open-label, Phase 2 study of PYRUKYND® (mitapivat) in adults with non-transfusion-dependent α- or β-thalassemia were published on August 11, 2022, in The Lancet.

Silence Therapeutics plc announced the pricing of an underwritten offering of 5,950,000 American Depositary Shares, each representing three ordinary shares, at a price of $9.50 per ADS, for aggregate gross proceeds of approximately $56.5 million, before deducting underwriting discounts and commissions and other offering expenses.

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced that it has terminated the underwritten public offering of its Class A common stock previously announced on August 10, 2022.

Nkarta, Inc., a clinical-stage biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, reported financial results for the second quarter ended June 30, 2022.